BRCA1 and BRCA2 mutations and the risk for colorectal cancer

被引:72
|
作者
Sopik, V. [1 ]
Phelan, C. [2 ]
Cybulski, C. [3 ]
Narod, S. A. [1 ]
机构
[1] Womens Coll Hosp, Womens Coll Res Inst, Familial Breast Canc Res, Toronto, ON M5G 1N8, Canada
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL 33647 USA
[3] Pomeranian Med Univ, Dept Genet & Pathol, Szczecin, Poland
关键词
aspirin; BRCA1; BRCA2; colonoscopy; colorectal cancer; prevention; BREAST-CANCER; FAMILY-HISTORY; OVARIAN-CANCER; FOLLOW-UP; VITAMIN-D; ASPIRIN; PREVENTION; CARRIERS; METAANALYSIS; FREQUENCY;
D O I
10.1111/cge.12497
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Women who carry a BRCA1 or BRCA2 mutation are at high risk of breast and ovarian cancer, and may be at moderately increased risk of other cancer types. This review examines studies to date that have evaluated the risk of BRCA1 and BRCA2 mutations for colorectal cancer. Accurate knowledge of colorectal cancer risk in BRCA1/2 carriers is important, because colonoscopy screening can prevent colorectal cancer through the removal of adenomatous polyps. Most studies that have identified an increased risk for colorectal cancer in BRCA1/2 mutation carriers were in high-risk cancer families, while studies that found no association were conducted in specific populations and involved the analysis of founder mutations. A recent prospective study of 7015 women with a BRCA1 or BRCA2 mutation identified significant fivefold increased risk of colorectal cancer among BRCA1 mutation carriers younger than 50 years [standardized incidence ratio (SIR): 4.8; 95% CI: 2.2-9], but not in women with a BRCA2 mutation or in older women. Based on this evidence, women with BRCA1 mutations should be counseled about their increased risk for early-onset colorectal cancer, and offered colonoscopy at 3- to 5-year intervals between the ages of 40 and 50 years, and should follow population guidelines thereafter.
引用
收藏
页码:411 / 418
页数:8
相关论文
共 50 条
  • [1] BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer
    Niell, BL
    Rennert, G
    Bonner, JD
    Almog, R
    Tomsho, LP
    Gruber, SB
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (01) : 15 - 21
  • [2] BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer
    Friedenson, B
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) : 1184 - 1185
  • [3] BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer - Response
    Rennert, G
    Bonner, JD
    Gruber, SB
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) : 1185 - 1186
  • [4] BRCA1 and BRCA2 founder mutations are not associated with a high risk of colorectal cancer.
    Niell, BL
    Rennert, G
    Tomsho, LP
    Bonner, JD
    Gruber, SB
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) : 253 - 253
  • [5] BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Buerkle, Bernd
    Tempfer, Clemens
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 359 - 359
  • [6] BRCA1 and BRCA2 Mutations and Breast Cancer
    Narod, Steven A.
    Salmena, Leonardo
    [J]. DISCOVERY MEDICINE, 2011, 12 (66) : 445 - 453
  • [7] Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations
    Lu Yao
    Jie Sun
    Juan Zhang
    Yingjian He
    Tao Ouyang
    Jinfeng Li
    Tianfeng Wang
    Zhaoqing Fan
    Tie Fan
    Benyao Lin
    Yuntao Xie
    [J]. Breast Cancer Research and Treatment, 2016, 156 : 441 - 445
  • [8] Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations
    Yao, Lu
    Sun, Jie
    Zhang, Juan
    He, Yingjian
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xie, Yuntao
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (03) : 441 - 445
  • [9] Pregnancy and breast cancer risk in women with BRCA1 or BRCA2 mutations
    Carol Lovegrove
    [J]. Nature Clinical Practice Oncology, 2006, 3 (1): : 9 - 9
  • [10] Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations
    Stephanie Kearton
    Karen Wills
    Michael Bunting
    Penny Blomfield
    Paul A. James
    Jo Burke
    [J]. Familial Cancer, 2018, 17 : 333 - 344